Literature DB >> 19609104

Dissociated responsiveness of a growth hormone- and thyrotropin-secreting pituitary adenoma to octreotide-long-acting release therapy: the intriguing case of Mister B.

L Curtò, M Ragonese, M Losa, F Trimarchi, S Cannavò.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19609104     DOI: 10.1007/BF03346583

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  5 in total

1.  Clinical and morphological features of undifferentiated monomorphous GH/TSH-secreting pituitary adenoma.

Authors:  T Skorić; M Korsić; K Zarković; V Plavsić; N Besenski; L Breskovac; Z Giljević; J Paladino
Journal:  Eur J Endocrinol       Date:  1999-06       Impact factor: 6.664

2.  Dramatic volume reduction of a large GH/TSH secreting pituitary tumor with short term Octreotide therapy.

Authors:  John L D Atkinson; Charles F Abboud; John I Lane
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  An unusual somatotropin and thyreotropin secreting pituitary adenoma efficiently controlled by Octreotide and Pegvisomant.

Authors:  T Meas; E Sobngwi; P Vexiau; P Boudou
Journal:  Ann Endocrinol (Paris)       Date:  2006-06       Impact factor: 2.478

4.  Endocrine, biochemical, and morphological studies of a pituitary adenoma secreting growth hormone, thyrotropin (TSH), and alpha-subunit: evidence for secretion of TSH with increased bioactivity.

Authors:  P Beck-Peccoz; G Piscitelli; S Amr; M Ballabio; M Bassetti; G Giannattasio; A Spada; M Nissim; B D Weintraub; G Faglia
Journal:  J Clin Endocrinol Metab       Date:  1986-04       Impact factor: 5.958

5.  Pituitary macroadenoma secreting thyrotropin and growth hormone: remission of bihormonal hypersecretion in response to lanreotide therapy.

Authors:  I Shimon; D Nass; D J Gross
Journal:  Pituitary       Date:  2001-09       Impact factor: 4.107

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.